Estimated market cap $6.18BShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Oct 27, 2026, last close Nov 13, 2026.20.00M shares, shares as of Oct 27, 2026CIK 886163The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
0 buys · 143 sells
$34.20M sold, open market
Congress trades, 24 mo
4
4 purchases, 0 sales
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Ligand Pharmaceuticals Incorporated's latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Executive-branch trades
1 trade
Trades in Ligand Pharmaceuticals Incorporated reported by the President, Cabinet members and other senior executive-branch officials. Amounts are ranges.Form 278-T is the periodic transaction report that senior executive-branch officials file with the Office of Government Ethics. They must report each trade over $1,000 within 30 days of being notified of it, and no later than 45 days after the trade. Amounts are ranges, not exact figures.
Recent executive-branch trades
Official
AssetThe form has no ticker column. The asset is shown as the filer wrote it. We add a ticker link only when we could match the asset to a listed company.
Type
Traded
AmountThe form asks for a range, such as $1,001 - $15,000, not an exact amount. A line can be left blank when the filer's note says the amount was not more than $1,000.
What Ligand Pharmaceuticals Incorporated and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
305
85.3% of shares · 109 added
Latest 10-Q
Q3 2026
What changed in Ligand Pharmaceuticals Incorporated's latest quarterly report, compared with the one before.
Filed Oct 30, 2026 · Quarter ended Sep 30, 2026
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
AI summary of changes vs the prior report. Written by AI from the paragraphs that changed, and checked against them. This is information, not investment advice.
Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
305 funds report LGND. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds report more than 100% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 22.67M reported shares by 19.94M shares, from the company’s SEC filing as of Aug 4, 2026.
416 funds hold the stock.
Q3 2026: 85% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202598%
Q3 2025>100%
Q4 2025>100%
Q1 2026>100%
Q2 2026>100%
Q3 2026 (so far)85%
Q3 2026. 40 new, 109 added to, 96 trimmed, 152 exited since Q2 2026.
Download CSVEvery fund that holds LGND, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
4 in 24 mo
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Recent congressional trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
What Ligand Pharmaceuticals Incorporated and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q2 2013
110
—
16.54M
$619.0M
Q3 2013
127
+17
16.44M
$712.4M
Q4 2013
159
+32
20.65M
$1.1B
Q1 2014
182
+23
20.82M
$1.4B
Q2 2014
192
+10
21.06M
$1.3B
Q3 2014
174
-18
22.10M
$1.0B
Q4 2014
180
+6
21.71M
$1.2B
Q1 2015
187
+7
22.47M
$1.7B
Q2 2015
215
+28
21.88M
$2.2B
Q3 2015
203
-12
23.18M
$2.0B
Q4 2015
233
+30
23.16M
$2.5B
Q1 2016
251
+18
26.08M
$2.8B
Q2 2016
265
+14
24.98M
$3.0B
Q3 2016
258
-7
24.66M
$2.5B
Q4 2016
269
+11
24.89M
$2.5B
Q1 2017
256
-13
24.73M
$2.6B
Q2 2017
265
+9
25.03M
$3.0B
Q3 2017
291
+26
24.62M
$3.4B
Q4 2017
297
+6
24.69M
$3.4B
Q1 2018
325
+28
24.82M
$4.1B
Q2 2018
345
+20
25.91M
$5.4B
Q3 2018
384
+39
24.54M
$6.7B
Q4 2018
360
-24
27.15M
$3.7B
Q1 2019
329
-31
26.09M
$3.3B
Q2 2019
304
-25
26.19M
$3.0B
Q3 2019
274
-30
23.35M
$2.3B
Q4 2019
266
-8
22.97M
$2.4B
Q1 2020
261
-5
23.29M
$1.7B
Q2 2020
263
+2
22.12M
$2.5B
Q3 2020
252
-11
22.96M
$2.2B
Q4 2020
242
-10
23.25M
$2.3B
Q1 2021
228
-14
15.42M
$2.4B
Q2 2021
212
-16
15.93M
$2.1B
Q3 2021
208
-4
16.41M
$2.3B
Q4 2021
220
+12
16.36M
$2.5B
Q1 2022
206
-14
14.87M
$1.7B
Q2 2022
197
-9
14.88M
$1.3B
Q3 2022
205
+8
16.12M
$1.4B
Q4 2022
198
-7
14.72M
$983.5M
Q1 2023
212
+14
14.89M
$1.1B
Q2 2023
204
-8
15.58M
$1.1B
Q3 2023
196
-8
15.65M
$937.7M
Q4 2023
211
+15
16.41M
$1.2B
Q1 2024
222
+11
17.06M
$1.2B
Q2 2024
235
+13
17.32M
$1.5B
Q3 2024
243
+8
18.18M
$1.8B
Q4 2024
258
+15
18.26M
$2.0B
Q1 2025
262
+4
18.73M
$2.0B
Q2 2025
271
+9
19.21M
$2.2B
Q3 2025
314
+43
20.56M
$3.6B
Q4 2025
352
+38
20.57M
$3.9B
Q1 2026
362
+10
20.81M
$4.2B
Q2 2026
416
+54
22.67M
$7.2B
Q3 2026
305
-111
17.06M
$5.3B
Each point is a quarter-end, from Q2 2013 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (53220K504). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2013) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.